Literature DB >> 31559971

Primary nonadherence to medication and its drivers in Poland: findings from the electronic prescription pilot analysis.

Przemysław Kardas1, Janusz Cieszyński2, Marcin Czech3, Izabela Banaś4, Paweł Lewek4.   

Abstract

INTRODUCTION: Primary nonadherence to medication occurs when a patient does not fill a prescription and often leads to suboptimal patient outcomes, lost productivity, and increased net costs. Pilot introduction of electronic prescriptions (e‑prescriptions) in Poland took place in 2018, enabling nationwide assessment of primary nonadherence.
OBJECTIVES: To determine the prevalence and drivers of primary nonadherence in Poland.
METHODS: This retrospective analysis included data from all e‑prescriptions issued in Poland in 2018. Primary nonadherence was defined as not filling a prescription within 1 month from the date of issuing.
RESULTS: Out of all 119 880 e‑prescriptions issued in Poland in 2018, 94 913 were filled, thus the primary nonadherence rate reached 20.8%. Although no differences in primary nonadherence were observed between sexes, age was found to have a significant effect, with older groups showing lower rates of primary nonadherence. In addition, slightly lower rates of primary nonadherence (17.0%) were found for e‑prescriptions issued for selected drugs of key importance (n = 47 492). Multivariable analysis performed within this subset showed that those aged ≥75 years had the lowest odds for nonadherence (odds ratio, 0.55; 95% CI, 0.48-0.64). Differences in primary nonadherence rates were observed across therapeutic areas (lowest value in antibiotics, 14.3%), drug classes (lowest value in sulfonylureas, 13.2%), and individual drugs. Primary nonadherence rates were lower for drugs covered by the "Leki 75+" program, which makes them free of charge for those aged 75 years or older.
CONCLUSIONS: A high percentage of prescriptions issued in Poland are never filled. E‑prescriptions allow the identification and analysis of drivers of this phenomenon. Our findings may help designing national health and medicine policies.

Entities:  

Mesh:

Year:  2019        PMID: 31559971     DOI: 10.20452/pamw.14994

Source DB:  PubMed          Journal:  Pol Arch Intern Med        ISSN: 0032-3772


  5 in total

1.  PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021.

Authors:  Maciej Banach; Paweł Burchardt; Krzysztof Chlebus; Piotr Dobrowolski; Dariusz Dudek; Krzysztof Dyrbuś; Mariusz Gąsior; Piotr Jankowski; Jacek Jóźwiak; Longina Kłosiewicz-Latoszek; Irina Kowalska; Maciej Małecki; Aleksander Prejbisz; Michał Rakowski; Jacek Rysz; Bogdan Solnica; Dariusz Sitkiewicz; Grażyna Sygitowicz; Grażyna Sypniewska; Tomasz Tomasik; Adam Windak; Dorota Zozulińska-Ziółkiewicz; Barbara Cybulska
Journal:  Arch Med Sci       Date:  2021-11-08       Impact factor: 3.318

2.  Primary non-adherence to inhaled medications measured with e-prescription data from Poland.

Authors:  Grzegorz Kardas; Michał Panek; Piotr Kuna; Przemysław Kardas
Journal:  Clin Transl Allergy       Date:  2020-10-07       Impact factor: 5.871

3.  Primary Non-Adherence to Antihistamines-Conclusions From E-Prescription Pilot Data in Poland.

Authors:  Grzegorz Kardas; Michał Panek; Piotr Kuna; Janusz Cieszyński; Przemysław Kardas
Journal:  Front Pharmacol       Date:  2020-05-21       Impact factor: 5.810

4.  The Need to Develop Standard Measures of Patient Adherence for Big Data: Viewpoint.

Authors:  Przemyslaw Kardas; Isabel Aguilar-Palacio; Marta Almada; Caitriona Cahir; Elisio Costa; Anna Giardini; Sara Malo; Mireia Massot Mesquida; Enrica Menditto; Luís Midão; Carlos Luis Parra-Calderón; Enrique Pepiol Salom; Bernard Vrijens
Journal:  J Med Internet Res       Date:  2020-08-27       Impact factor: 5.428

5.  Prevalence and Age Structure of Polypharmacy in Poland: Results of the Analysis of the National Real-World Database of 38 Million Citizens.

Authors:  Przemysław Kardas; Filip Urbański; Aneta Lichwierowicz; Ewa Chudzyńska; Grzegorz Kardas; Marcin Czech
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.